Avalo Therapeutics (AVTX) Asset Writedowns and Impairment (2018)
Avalo Therapeutics (AVTX) reported Asset Writedowns and Impairment of $159687.0 for Q3 2018, down 90.62% quarter-over-quarter from $1.7 million in Q2 2018.
Avalo Therapeutics (AVTX) Asset Writedowns and Impairment (2018) Analysis & Trends
Avalo Therapeutics has reported Asset Writedowns and Impairment for 1 years, with the latest figure at $159687.0 in Q3 2018.
- For the quarter ending Q3 2018, Asset Writedowns and Impairment changed N/A year-over-year to $159687.0; the trailing twelve-month figure through Dec 2019 stood at $159687.0 (down 91.42% YoY), and the FY2019 full-year result was $1.4 million, down 22.16% from the prior year.
- Asset Writedowns and Impairment for Q3 2018 stood at $159687.0, down from $1.7 million in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $1.7 million in Q2 2018, with the low at $159687.0 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Avalo Therapeutics | 295.77 Mn | 295.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 159,687.00 |
| Sep 30, 2018 | 159,687.00 |
| Jun 30, 2018 | 1.70 Mn |
| Jun 30, 2018 | 1.70 Mn |